Calumet shares rise after analyst highlights MaxSAF-driven EBITDA growth and debt reduction potential.
Latest Ratings for CLMT
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Feb 2022 | HC Wainwright & Co. | Maintains | Buy | |
| Nov 2021 | Wolfe Research | Upgrades | Peer Perform | Outperform |
| Nov 2021 | Cowen & Co. | Upgrades | Market Perform | Outperform |
